Leslie McLean, MD
Hospice and Palliative Medicine · Gillette, WYNPI 1396753943
Payments from drug & device makers
Across 16 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$68
- Lilly USA, LLC$61
- Novo Nordisk$36
- AstraZeneca$35
- GSK$34
- Merck$33
- plus $17 from 1 others
What the payments were for
- Food & beverage$284100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $68 |
| Lilly USA, LLC | 4 | $61 |
| Novo Nordisk | 2 | $36 |
| AstraZeneca | 1 | $35 |
| GSK | 2 | $34 |
| Merck | 2 | $33 |
| Urogen Pharma, Inc. | 1 | $17 |
How this compares
Too few hospice and palliative medicine providers in Wyomingto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 75 | $94,656 |
| TrulicityDulaglutide | 66 | $81,411 |
| OzempicSemaglutide | 81 | $76,887 |
| JardianceEmpagliflozin | 19 | $31,200 |
| FarxigaDapagliflozin Propanediol | 15 | $25,000 |
| JanuviaSitagliptin Phosphate | 16 | $24,694 |
| MounjaroTirzepatide | 22 | $21,822 |
| XareltoRivaroxaban | 21 | $16,667 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $15,566 |
| Spiriva RespimatTiotropium Bromide | 26 | $14,516 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 39 | $13,388 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $6,718 |
| PremarinEstrogens, Conjugated | 12 | $6,019 |
| Rosuvastatin Calcium | 274 | $4,077 |
| Omeprazole | 244 | $3,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $61 | $103,23388 claims |
| Novo NordiskOzempic | $36 | $76,88781 claims |
| AstraZenecaFarxiga, Symbicort | $35 | $27,83627 claims |
| MerckJanuvia | $33 | $24,69416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hospice and palliative medicine providers in Wyomingon file to place this against a meaningful peer group, so we don't.
Other hospice and palliative medicine in Gillette
- Christina Elize JaraCasper$389
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.